Cardiovascular Disease

PCSK9 Inhibitor Tolerability Examined in Patients With Self-Reported Statin Intolerance

By October 17, 2018

The study utilized patient-reported side effects to determine the tolerability of the PCSK9 inhibitors evolocumab and alirocumab.

Harvard: Heart Researcher's Papers Contain Fraudulent Data

October 17, 2018

Anversa has published more than 100 scientific papers, has collaborated with leaders in the field of heart research, and was honored as a distinguished scientist by the American Heart Association, the Post reported.

Class 1 Device Recall: Endologix AFX Device Recalled Due to Type III Endoleaks

October 16, 2018

The US Food and Drug Administration has identified this as a Class I recall, with continued device use resulting in serious injury or death.

β-Blocker Use in First Trimester and Congenital Malformations Risk Examined

October 16, 2018

Researchers estimated the risks for major congenital malformations associated with first-trimester exposure to β-blockers using data from health registries in the 5 Nordic countries and the US Medicaid database.

FDA: Medtronic Update Addresses Cybersecurity Issue With CIED Programmers

By October 15, 2018

The vulnerability is associated with using an internet connection to update software between the Medtronic CareLink and CareLink Encore Programmers (models 2090 and 29901) and the Medtronic Software Distribution Network (SDN).

Xarelto Approved to Reduce Risk of Major Cardiovascular Events in Patients With CAD, PAD

By October 12, 2018

The FDA approval was supported by data from the Phase 3 COMPASS trial (N=27,395) which evaluated Xarelto with or without aspirin for the long-term prevention of major adverse CV events (including MI, stroke, CV death) in patients with chronic CAD or PAD.

Cardiovascular Safety of Revefenacin as COPD Treatment Examined

October 12, 2018

No changes were observed in 12-lead electrocardiographic recordings associated with daily doses of revefenacin 88 μg and 175 μg in patients with COPD.

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

October 12, 2018

Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.

Continuous, extended combined oral contraceptive regimens and VTE risk

October 11, 2018

In this retrospective cohort study, continuous (84/7) or extended (365/0) cycle regimens of combined oral contraceptives were not linked with meaningfully higher rates of venous thromboembolism (VTE) when compared with traditional cyclic (21/7) regimens.

Aclidinium Bromide May Increase MACE Risk in Those With CV Risk Factors

October 11, 2018

Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.

Macitentan Tolerated in Portopulmonary Hypertension

October 11, 2018

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

By October 10, 2018

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Statins May Decrease the Risk for Active Tuberculosis

October 09, 2018

The use of statins may decrease the risk for active tuberculosis.

Sustained Hepatitis C Tx Associated With Lower Risk for Cardiovascular Events

October 09, 2018

Treatment for hepatitis C is associated with a reduction in cardiovascular events.

Sexual Harassment, Assault Tied to Women's Health Issues

October 05, 2018

Among women not taking antihypertensives, sexual harassment was correlated with significantly increased odds of stage 1 or 2 hypertension (odds ratio, 2.36) as well as clinically poor sleep (odds ratio, 1.89) after adjustment for covariates.

Treatment for Transthyretin Amyloidosis Granted Orphan Drug Designation

By October 04, 2018

The Company expects to start Phase 3 studies for ATTR cardiomyopathy and polyneuropathy in the first half of 2019.

Southern diet may be largest factor in higher hypertension rates in black populations

October 03, 2018

The higher rate of hypertension in black patients than white patients was most strongly influenced by a Southern diet in both men and women.

Atorvastatin loading before PCI improves outcomes in patients with acute coronary syndrome

October 03, 2018

Patients with acute coronary syndrome who received a loading dose of atorvastatin prior to percutaneous coronary intervention and again 24 hours post-PCI had lower rates of major adverse cardiovascular events at 30 days compared with patients who received placebo.

Is a Physician Liable When a Patient Fails to Follow Discharge Instructions?

By October 02, 2018

Dr C was determined to fight this case, and his defense attorney was supportive after looking at the detailed notes and documented calls to the patient which were never returned.

Patient Develops Acquired Hemophilia After Treatment With Levofloxacin

By September 27, 2018

Although discontinuation of the medication resolved the patient's symptoms initially, spontaneous bruising recurred and progressed over several weeks, prompting the patient to seek medical attention for persistent bruising in her upper extremities.

PCI, CABG Both Acceptable for CKD Patients With Left Main Coronary Artery Disease

September 27, 2018

Compared to patients without CKD, those with CKD had higher 3-year rates of the primary end point (composite of death, myocardial infarction, or stroke [20.8 vs 13.5%; hazard ratio, 1.60]).

Rivaroxaban does not decrease rates of venous thromboembolism complications

September 26, 2018

At a median follow-up of 3.3 years, rates of symptomatic venous thromboembolism or death due to thromboembolism were similar for medically ill patients treated with rivaroxaban or placebo for 45 days following hospital discharge.

FDA Approves Eluvia Drug-Eluting Stent for Peripheral Artery Disease Treatment

By September 24, 2018

The Eluvia stent is designed to release paclitaxel for a 1-year time frame to prevent tissue regrowth that might otherwise block the stented artery.

Tafamidis improves all-cause mortality in transthyretin amyloid cardiomyopathy

September 21, 2018

In a phase 3 randomized control trial, tafamidis was shown to have associations with greater reductions in all-cause mortality and cardiovascular related hospitalizations compared to placebo among participants with transethyretin amyloid cardiomyopathy.

FDA: Final Guidance on Heparin-Containing Devices, Combo Products

By September 19, 2018

The intent of the document is to help reduce heparin product overdose errors caused by misinterpretation of the drug strength displayed in the labeling.

HTN Tx Intensification Common Upon Discharge in US Vets

September 19, 2018

Fourteen percent of patients were discharged with intensified antihypertensive treatment, more than half of whom had well-controlled blood pressure prior to hospital admission.

Hydralazine Linked to Amenorrhea in Premenopausal Patient

By September 18, 2018

This case highlights a possible relationship between the administration of hydralazine and the development of amenorrhea.

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

September 18, 2018

Tafamidis was also associated with a lower rate of decline in distance for the 6-minute walk test and a lower rate of decline in Kansas City Cardiomyopathy Questionnaire-Overall Summary score at month 30.

FDA Approves New Stent System to Treat Acute Coronary Artery Perforations

By September 17, 2018

The Agency reviewed real-world data from 80 patients who received the PK Papyrus Stents, finding that the stents were delivered successfully to the perforation site in 95% of patients with successful seals seen in 73 patients 91.3% of patients.

Use of Aspirin in Healthy Elderly Questioned in Three Studies

September 17, 2018

The researchers found that the rate of cardiovascular disease was 10.7 and 11.3 events per 1000 person-years in the aspirin and placebo groups, respectively (hazard ratio, 0.95; 95% confidence interval, 0.83 to 1.08).